In the course of our program to discover antimalarial antibiotics active against drug-resistant parasites, by screening soil microorganisms and antibiotic library of the Kitasato Institute for Life Sciences, we previously reported on various microbial metabolites exhibiting potent antimalarial properties1-4). Now, we find that prumycin5-7), a compound in the antibiotic library of our institute, has potent and moderately selective antimalarial activity in vitro and in vivo. We report here the antimalarial profiles of prumycin and its derivatives ( Fig. 1 ) in comparison with those of clinically used antimalarial drugs, and also present some conclusions on structure-activity relationships.
Prumycin was purified from the cultured broth of Streptomyces sp. strain No. F-10285,6). The derivatives (2-4) were synthesized according to our previous report7). Benzyl 4-amino-2-(benzyloxycarbonyl) amino-2,4-Nippon Kayaku Co. LTD., (Japan). The compounds (6-8)
were prepared from 5 with the protected amino acids (DCC, CH2Cl2, r.t.), followed by deprotections.
In vitro activities against Plasmodium falciparum strains K1 (drug-resistant) and FCR3 (drug-sensitive), and cytotoxicity against human diploid embryonic cell line MRC-5, were measured as described previously1). Rodent malaria-derived strains for in vivo 4-days suppressive testing, P. berghei N (drug-sensitive) and P. yoelii ssp. NS (chloroquine-resistant) were used to assess in vivo efficacy as reported previously1,2). Prumycin was dissolved in water, while other test compounds were solubilized in 10% DMSO-Tween 80 aqueous solution. The formulated samples were administered subcutaneously (s.c.) to mice two hours after infection with parasites (Day 0), and then once a day for 3 days (Days 1-3). On the day after the last treatment (Day 4), thin blood films were made from the tail blood of the mice, and the parasitaemia was determined as described previously2). Table 1 shows the in vitro antimalarial activities of prumycin, its derivatives and some standard antimalarial choroguine against the drug-resistant K1 strain of P.
falciparum, but were less potent than the clinically used antimalarials artemether, artemisinin and artesunate.
activities against the drug-sensitive FCR3 strain of P.
falciparum. However, the IC50 values of prumycin and acetylating the two primary amino groups (resulting in 4) destroys activity. Furthermore, replacement of the L-alanine group on the amino moiety at C-4 with, respectively, L-glycine (6), L-prohne (7), and L-isoleucine (8) also destroys activity. These results suggest that a free anomer at C-1, amino groups at C-2, and the methyl group at L-alanine all play an important role in the antimalarial activity of prumycin.
Further studies are necessary to extend the structureactivity relationships of prumycin-related antimalarial compounds. Table 2 shows a preliminary comparison of the in vivo subcutaneous antimalarial activities of prumycin and the standard antimalarial drugs. Prumycin had moderate activity against both rodent malaria-derived P. berghei N and P. yoelii ssp. NS, but was less effective than the clinically used antimalarials artemether and artesunate.
The ED90 value of prumycin (27.8mg/kg) against the chloroquine-resistant strain (P. yoelii ssp. NS) was much lower than that of chloroquine (>100mg/kg), and was similar to that of artesunate.
It is known that prumycin has inhibitory activities against phytopathogenic fungi such as Sclerotinia sclerotiorum and Botorytis cineria5,6), and against tumor cells8-11), and that its mode of anti-fungal action in growing cells of B. cineria involves selective inhibition of protein synthesis12).
Furthermore, we previously reported that it inhibits both protein synthesis and DNA synthesis in cultured HeLa S3 cells8). However, the finding of the antimalarial activities of prumycin and its derivative is novel and the above data are the first report of such properties.
We previously reported that the LD50 values (iv. and i.p., in mice) of prumycin were 144 and 155mg/kg, respectively.
However, we did observe toxicity (loss of weight, mortality) when the compound was delivered by the s.c. route further.
The above results reveal that prumycin is a promising lead compound for a new type of antimalarial drug. Further investigation of the antimalarial potential of prumycin is in progress. 
